Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

DLB US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Dolby Laboratories, Inc. Class A(DLB US)

$63.61-0.981.52%Ext:$60.61-3.004.72%(Market Closed · 01:00:02 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Categorized
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

DLB US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Dolby Laboratories, Inc. Class A(DLB US)

$63.61-0.981.52%Ext:$60.61-3.004.72%(Market Closed · 01:00:02 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Categorized
Chronological
By Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees
Chronological
By Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees

Chronological SEC Filings

Chronological SEC Filings

Non-Ownership Filings(395)

Expand
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers13 Nov
  • S-8Registration statement (employee benefit plan)11 Sep
  • 8-KDolby Laboratories Announces Leadership Transition27 Aug
  • 10-QQ3ended 26 Jun 202630 Jul
  • 8-KDolby Laboratories Reports Third Quarter 2026 Financial Results30 Jul
  • SDSD29 May
  • 10-QQ2ended 27 Mar 202630 Apr
  • 8-KDolby Laboratories Reports Second Quarter 2026 Financial Results30 Apr
  • 8-KSubmission of Matters to a Vote of Security Holders6 Feb
  • 10-QQ1ended 26 Dec 202529 Jan
  • 8-KDolby Laboratories Reports First Quarter 2026 Financial Results29 Jan
  • ARSAnnual report to security holders16 Dec 2025
  • DEFA14ADefinitive additional materials16 Dec 2025
  • DEF 14ADefinitive proxy statement16 Dec 2025
  • 10-KFY 2025ended 26 Sept 202518 Nov 2025
  • 8-KDolby Laboratories Reports Fourth Quarter and Fiscal Year 2025 Financial18 Nov 2025
  • 8-K2026 DOLBY EXECUTIVE BONUS PLAN14 Nov 2025
  • 10-QQ3ended 27 Jun 202531 Jul 2025
  • 8-KDolby Laboratories Reports Third Quarter 2025 Financial Results31 Jul 2025
  • SDSD29 May 2025

Ownership Filings(2K)

Expand
  • SC 13G/ADolby Laboratories, Inc.13 Nov
  • SC 13GDolby Laboratories, Inc.27 Oct
  • SC 13G/ADolby Laboratories, Inc.22 Oct
  • Form 4Couling John D5 Oct
  • Form 4DAGMAR DOLBY TRUST UNDER DOLBY FAMILY TRUST INSTRUMENT DATED MAY 7, 19992 Oct
  • Form 144Couling John D1 Oct
  • Form 4Whitten Marc17 Sep
  • Form 4Couling John D17 Sep
  • Form 4SHERMAN MARK ANDREW17 Sep
  • Form 4Couling John D3 Sep
  • Form 144Couling John D1 Sep
  • Form 4DAGMAR DOLBY TRUST UNDER DOLBY FAMILY TRUST INSTRUMENT DATED MAY 7, 199928 Aug
  • Form 3Whitten Marc28 Aug
  • Form 4Nicholson Ryan27 Aug
  • Form 144Nicholson Ryan25 Aug
  • Form 4Revankar Shriram18 Aug
  • Form 144Revankar Shriram14 Aug
  • Form 4Nicholson Ryan12 Aug
  • Form 144Nicholson Ryan10 Aug
  • Form 4Nicholson Ryan6 Aug

Non-Ownership Filings(395)

Expand
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers13 Nov
  • S-8Registration statement (employee benefit plan)11 Sep
  • 8-KDolby Laboratories Announces Leadership Transition27 Aug
  • 10-QQ3ended 26 Jun 202630 Jul
  • 8-KDolby Laboratories Reports Third Quarter 2026 Financial Results30 Jul
  • SDSD29 May
  • 10-QQ2ended 27 Mar 202630 Apr
  • 8-KDolby Laboratories Reports Second Quarter 2026 Financial Results30 Apr
  • 8-KSubmission of Matters to a Vote of Security Holders6 Feb
  • 10-QQ1ended 26 Dec 202529 Jan
  • 8-KDolby Laboratories Reports First Quarter 2026 Financial Results29 Jan
  • ARSAnnual report to security holders16 Dec 2025
  • DEFA14ADefinitive additional materials16 Dec 2025
  • DEF 14ADefinitive proxy statement16 Dec 2025
  • 10-KFY 2025ended 26 Sept 202518 Nov 2025
  • 8-KDolby Laboratories Reports Fourth Quarter and Fiscal Year 2025 Financial18 Nov 2025
  • 8-K2026 DOLBY EXECUTIVE BONUS PLAN14 Nov 2025
  • 10-QQ3ended 27 Jun 202531 Jul 2025
  • 8-KDolby Laboratories Reports Third Quarter 2025 Financial Results31 Jul 2025
  • SDSD29 May 2025

Ownership Filings(2K)

Expand
  • SC 13G/ADolby Laboratories, Inc.13 Nov
  • SC 13GDolby Laboratories, Inc.27 Oct
  • SC 13G/ADolby Laboratories, Inc.22 Oct
  • Form 4Couling John D5 Oct
  • Form 4DAGMAR DOLBY TRUST UNDER DOLBY FAMILY TRUST INSTRUMENT DATED MAY 7, 19992 Oct
  • Form 144Couling John D1 Oct
  • Form 4Whitten Marc17 Sep
  • Form 4Couling John D17 Sep
  • Form 4SHERMAN MARK ANDREW17 Sep
  • Form 4Couling John D3 Sep
  • Form 144Couling John D1 Sep
  • Form 4DAGMAR DOLBY TRUST UNDER DOLBY FAMILY TRUST INSTRUMENT DATED MAY 7, 199928 Aug
  • Form 3Whitten Marc28 Aug
  • Form 4Nicholson Ryan27 Aug
  • Form 144Nicholson Ryan25 Aug
  • Form 4Revankar Shriram18 Aug
  • Form 144Revankar Shriram14 Aug
  • Form 4Nicholson Ryan12 Aug
  • Form 144Nicholson Ryan10 Aug
  • Form 4Nicholson Ryan6 Aug